Avadel Pharma (NASDAQ: AVDL) reported Q1 EPS of ($0.30), $0.07 worse than the analyst estimate of ($0.23). Revenue for the quarter came in at $27.18 million versus the consensus estimate of $26.17 million.

For earnings history and earnings-related data on Avadel Pharma (AVDL) click here.